Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

BMO Capital Markets sustained its positive outlook on AbbVie Inc . (NYSE:ABBV) shares, maintaining an Outperform rating and a $208.00 price target. The firm's analyst, Evan David Seigerman, emphasized ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory ...

Vicks once again achieved the top monthly spot for TV impressions, while iSpot noted that pharma brands generated more year-over-year returns from sports and news cables compared to 2023.

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...